Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

506.82
+8.851.78%
Post-market: 506.820.00000.00%19:30 EDT
Volume:500.11K
Turnover:251.89M
Market Cap:21.74B
PE:18.13
High:509.53
Open:502.75
Low:492.90
Close:497.97
52wk High:609.35
52wk Low:395.00
Shares:42.89M
Float Shares:39.35M
Volume Ratio:0.75
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.40
PE(LYR):18.19

Loading ...

United Therapeutics Announces New Accelerated Share Repurchase

TIPRANKS
·
Yesterday

United Therapeutics CEO Martine Rothblatt Disposes of Common Shares Worth $4.64 Million

Reuters
·
Yesterday

United Therapeutics to Repurchase $478 Million of Shares

MT Newswires Live
·
Sep 08

United Therapeutics Corporation - Final Settlement of Asr Expected in Q4 2026

THOMSON REUTERS
·
Sep 08

United Therapeutics Corporation - to Pay $477.60 Mln to Citi on or Around Sept 10, 2026

THOMSON REUTERS
·
Sep 08

United Therapeutics Corporation - to Receive Initial Delivery of 75% of Repurchased Shares Based on Sept 8, 2026 Price

THOMSON REUTERS
·
Sep 08

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization

THOMSON REUTERS
·
Sep 08

United Therapeutics CEO Martine Rothblatt Reports Disposal of 9,406 Common Shares Worth $4.64 Million

Reuters
·
Sep 04

Wells Fargo Reaffirms Their Buy Rating on United Therapeutics (UTHR)

TIPRANKS
·
Sep 02

Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and Medtronic (MDT)

TIPRANKS
·
Sep 02

United Therapeutics Says FDA Accepts Tyvaso sNDA for Idiopathic Pulmonary Fibrosis Review

Reuters
·
Sep 02

United Therapeutics Corporation - FDA Review Expected to be Complete in Late April 2027

THOMSON REUTERS
·
Sep 02

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

THOMSON REUTERS
·
Sep 02

United Therapeutics Chairperson, CEO Rothblatt Disposes of Common Shares Worth $4.85 Million

Reuters
·
Sep 02

United Therapeutics Executives to Speak at Wells Fargo Healthcare Investor Conference

Reuters
·
Sep 01

United Therapeutics (UTHR) Will Present Phase 3 Data At European Congresses

Simply Wall St.
·
Aug 30

United Therapeutics Chairperson and CEO Martine Rothblatt Disposes of 7,500 Common Shares for $3.93 Million

Reuters
·
Aug 29

United Therapeutics Submits FDA NDA for PAH Drug Ralinepag

Reuters
·
Aug 28

RBC Capital Sticks to Its Buy Rating for United Therapeutics (UTHR)

TIPRANKS
·
Aug 27

United Therapeutics Chairperson, CEO Rothblatt Sells 9,500 Shares for $4.92 Million

Reuters
·
Aug 27